AHA collaborates with new not-for-profit generic drug company to support inquiries

Civica Rx, the initiative previously known as Project Rx, is a new not-for-profit generic drug company that seeks to help patients by addressing shortages and high prices of lifesaving medications.

Civica Rx will be a Food and Drug Administration-approved manufacturer and will either directly manufacture generic drugs or sub-contract manufacturing to reputable contract manufacturing organizations. The company will first seek to stabilize the supply of essential generic medications administered in hospitals, many of which have fallen into chronic shortage situations, putting patients at risk. It has identified 14 hospital-administered generic drugs as the initial focus of the company’s efforts.

The initiative will also result in lower costs and more predictable supplies of essential generic medicines, helping ensure that patients and their needs come first in the generic drug marketplace. Civica Rx expects to have its first products on the market as early as 2019, and in the near future, also expects to provide generic medications to the retail market, offering an affordable alternative to products from incumbent generic drug companies.

Initial governing members of Civica Rx will include Catholic Health Initiatives, HCA Healthcare, Intermountain Healthcare, Mayo Clinic, Providence St. Joseph Health, SSM Health, and Trinity Health. These seven organizations, representing about 500 U.S. hospitals, will each provide leadership for the Civica Rx Board of Directors and will provide much of the initial capitalization for the company. The U.S. Department of Veterans Affairs will also work in consultation with Civica Rx to address its particular needs.


The AHA Center for Health Innovation is collaborating with Civica Rx to address inquiries about the initiative. Please call 800.242.4677 with questions.